protein kinase C delta inhibitor / BriaCell, BriaPro Therap - LARVOL DELTA

BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. (GlobeNewswire) - "BriaCell Therapeutics...announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp. ('SpinCo'), a wholly-owned subsidiary of the Company (the 'Arrangement Agreement') pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the 'SpinCo Assets'), will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia) (the 'Arrangement'). 'As we focus our efforts on the upcoming pivotal study of our lead clinical candidate, Bria-IMT™, in advanced metastatic breast cancer, we believe that this strategy of spinning out certain pre-clinical immunotherapies in a separate entity of BriaPro Therapeutics Corp. will position them for success and will create our shareholders value over the long term.'"

Licensing / partnership • Preclinical • Immunology • Oncology • Systemic Sclerosis